Back to top
more

Retrophin, Inc. (RTRX)

(Delayed Data from NSDQ)

$19.72 USD

19.72
376,763

+0.61 (3.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $19.75 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.57%
2Buy19.14%
3Hold10.74%
4Sell6.46%
5Strong Sell3.16%
S&P50011.27%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Brokerage Reports

0 items in cart

Travere Therapeutics, Inc. [RTRX]

Reports for Purchase

Showing records 1 - 20 ( 35 total )

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

11/06/2020

Daily Note

Pages: 27

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

11/06/2020

Company Report

Pages: 9

Commercial Execution, Catalysts Ahead - Much To Like For RTRX In 3Q20 Report

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

10/23/2020

Daily Note

Pages: 16

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

10/23/2020

Daily Note

Pages: 4

Opting For More Orphan - A Good Thing

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 10.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

10/19/2020

Daily Note

Pages: 30

It''s That Time Again; 3Q20 Commercial Preview

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 75.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

10/09/2020

Industry Report

Pages: 10

Kidney KOL Call Takeaways: Double The Fun - Closer Look At Sparsentan, FSGS

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

09/21/2020

Company Report

Pages: 4

PROTECTing The Readout Timing - PROTECT Study Reaches Interim Enrollment Target

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 10.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

09/18/2020

Daily Note

Pages: 6

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

09/17/2020

Company Report

Pages: 50

We are initiating coverage with an Outperform rating and $33 target

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 100.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

03/11/2020

Industry Report

Pages: 2

Dial In to Part 1 of Our FSGS Expert Call Series Today at 11am ET

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for RTRX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

07/01/2014

Company Report

Pages: 4

We are dropping coverage of Retrophin, Inc -as we are focusing our efforts elsewhere in the biotechnology sector

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

06/02/2014

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

05/30/2014

Company Report

Pages: 4

Further Thiola Details to Drive Revenue Growth; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

05/30/2014

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

05/30/2014

Company Report

Pages: 6

Further Pipeline and Revenue Build Bolstering Company Strategy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

05/15/2014

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

05/14/2014

Company Report

Pages: 6

1Q14 Results; RE-024 Dosing Set to Begin This Week; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

05/13/2014

Company Report

Pages: 7

PKAN Moves Forward; Tweaking Projections; Off Focus List; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

05/13/2014

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party